Skip to main content
Log in

Development and evaluation of an anti-candida cream based on silver nanoparticles

  • Original Article
  • Published:
3 Biotech Aims and scope Submit manuscript

Abstract

The ineffectiveness of azole drugs in treating Vulvovaginal Candidiasis (VVC) and Recurrent Vulvovaginal Candidiasis (RVVC) due to antifungal resistance of non-albicans Candida has led to the investigation of inorganic nanoparticles with biological activity. Silver nanoparticles (AgNPs) are important in nanomedicine and have been used in various products and technologies. This study aimed to develop a vaginal cream and assess its in vitro antimicrobial activity against Candida parapsilosis strains, specifically focusing on the synergy between AgNPs and miconazole. AgNPs were synthesized using glucose as a reducing agent and sodium dodecyl sulfate (SDS) as a stabilizer in varying amounts (0.50, 0.25, and 0.10 g). The AgNPs were characterized using UV–Visible (UV–Vis) and Fourier-Transform Infrared (FT-IR) spectroscopies, X-Ray Diffraction (XRD), Dynamic Light Scattering (DLS), Scanning Electron Microscopy (SEM), and Energy Dispersive X-Ray Analysis (EDX). Fifty strains of Candida parapsilosis were used to evaluate the synergistic activity. AgNPs synthesized with 0.5 g SDS had an average size of 77.58 nm and a zeta potential of −49.2 mV, while AgNPs with 0.25 g showed 91.22 nm and −47.2 mV, respectively. AgNPs stabilized with 0.1 g of SDS were not effective. When combined with miconazole, AgNPs exhibited significant antifungal activity, resulting in an average increase of 80% in inhibition zones. The cream developed in this study, containing half the miconazole concentration of commercially available medication, demonstrated larger inhibition zones compared to the commercial samples.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

Not applicable.

References

Download references

Acknowledgements

The authors thank Central Analítica-UFC/CT-INFRA/MCTI-SISNANO/Pró-Equipamentos for providing the SEM experiments and X-ray Diffraction Laboratory (LRX-UFC). This work was partially supported by NanoSaude: E-26/010.000981/2019, UEZO: E-26/010.002362/2019; Temáticos: E-26/211.269/2021, Infraestrutura and Pesquisa na UEZO, UERJ: E-26//211.207/2021, Bolsa de Pós-Doutorado Senior (PDS): E-26/202.320/2021 and CNPq (Bolsa de Produtividade 1C: 308452/2022-4 and 1B: 301069/2018-2). This work was also supported by CAPES (Finance Code 001-PROEX 23038.000509/2020-82) and Funcap (PNE-0112-00048.01.00/16).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pierre Basílio Almeida Fechine.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Ethical approval

This study did not involve the use of any human or animal model.

Informed consent

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maciel, A.A.M., Cunha, F.A., Freire, T.M. et al. Development and evaluation of an anti-candida cream based on silver nanoparticles. 3 Biotech 13, 352 (2023). https://doi.org/10.1007/s13205-023-03776-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13205-023-03776-9

Keywords

Navigation